In a rare display of cross-party unity, lawmakers from both sides of the aisle have introduced legislation aimed at expanding Medicare coverage for a new generation of blood tests that can detect Alzheimer's disease in its earliest stages. The ASAP Act (Access to Simple Alzheimer's testing Program) would direct the Secretary of Health and Human Services to establish a coverage pathway for FDA-approved blood-based biomarker tests, a move that could radically reshape how the disease is diagnosed and treated.
The bill, spearheaded by Rep. Vern Buchanan (R-Fla.) and Rep. Paul Tonko (D-N.Y.), reflects a shared recognition that Alzheimer's is a looming public health crisis. With over 7 million Americans currently living with the disease—and that number projected to nearly double in the coming decades—the lawmakers argue that early detection is not just a medical priority but a fiscal necessity. "Alzheimer's doesn't care about politics," they wrote in a joint statement. "It affects families in every state, congressional district, and neighborhood across America."
Currently, Medicare coverage for preventive services is limited to those explicitly authorized by Congress or recommended by the U.S. Preventive Services Task Force. That process can lag years behind FDA clearance, leaving patients without access to cutting-edge diagnostics. Blood-based biomarker tests, which can identify Alzheimer's pathology more than a decade before symptoms appear, have been cleared by the FDA but remain largely uncovered, forcing patients to pay hundreds of dollars out of pocket.
The ASAP Act seeks to close that gap. By authorizing Medicare to cover these tests, the bill would remove a major financial barrier, particularly for seniors in rural and underserved communities where access to specialists and advanced imaging is limited. "A simple blood test could reduce the burden of traveling long distances for care," the lawmakers noted, underscoring the equity implications of the legislation.
Early detection is critical because Alzheimer's is one of the most expensive diseases to manage. Late-stage care often requires extensive medical services and long-term support, imposing significant costs on families and taxpayers alike. The Congressional Budget Office has projected that spending on Alzheimer's and other dementias could exceed $1 trillion by 2050. By catching the disease earlier, the ASAP Act could help families plan, pursue treatment, and potentially slow progression, easing the financial and emotional toll on caregivers.
Cost-effectiveness is a key selling point. Blood tests are far less expensive than PET scans, making them a more fiscally responsible option for Medicare. "Modern blood tests are much softer on taxpayers than a typical PET scan," the lawmakers argued, addressing concerns about budget impact. The bill also aligns with broader bipartisan efforts to rein in healthcare costs and promote innovation, themes that have gained traction amid bipartisan talks on executive power and congressional oversight.
The legislation has already garnered significant support, with 224 House co-sponsors. That momentum, the sponsors say, signals a genuine appetite for action. "Every month we delay costs Americans opportunities to benefit from advances that could make a meaningful difference in their lives," they wrote. "The time for waiting is over. We must act ASAP."
Drawing a parallel to the 1990 decision to cover mammograms, Buchanan and Tonko see the ASAP Act as a historic opportunity. "In 1990, Congress voted to ensure Medicare coverage of mammograms, saving the lives of millions of women through early detection," they recalled. "Today, we have the chance to change Alzheimer's trajectory and write a new story."
As the population ages, the pressure to act grows. The bill represents a convergence of interests—Republicans championing innovation and fiscal restraint, Democrats pushing for equity and access. Whether it can clear the legislative hurdles remains to be seen, but for now, it stands as a testament to what can happen when lawmakers focus on a disease that affects us all.
